Filtered By:
Source: Expert Review of Cardiovascular Therapy
Condition: Bleeding

This page shows you your search results in order of date.

Order by Relevance | Date

Total 26 results found since Jan 2013.

Can Warfarin be replaced by non-vitamin K anticoagulants in prosthetic valves?
In this report, the authors discussed the published data related to NOACs use in prosthetic valves highlighting the proposed mechanisms of NOACs failure and other controversial data regarding their efficacy and safety in prosthetic valves.EXPERT OPINION: Although NOACs have proven to be even safer and more effective alternatives to vitamin K antagonists (VKAs) in several indications for anticoagulation, the data regarding their safety and efficacy in prosthetic heart valves is still debatable. The controversial data regarding NOACs use in prosthetic valves renders it difficult to define specific guideline-recommendation fo...
Source: Expert Review of Cardiovascular Therapy - November 24, 2022 Category: Cardiology Authors: Mahmoud Abdelnabi Juthipong Benjanuwattra Ashraf Ahmed Abdallah Almaghraby Source Type: research

Safety and efficacy of transcatheter aortic valve implantation in stenotic bicuspid aortic valve compared to tricuspid aortic valve: a systematic review and meta-analysis
CONCLUSION: The use of TAVI for the treatment of aortic stenosis in selective BAV appears to be safe and effective.PMID:35770517 | DOI:10.1080/14779072.2022.2094368
Source: Expert Review of Cardiovascular Therapy - June 30, 2022 Category: Cardiology Authors: Mohamed Zghouzi Heba Osman Waqas Ullah Abdul-Rahman Suleiman Parveen Razvi Mukhlis Abdalrazzak Firas Rabbat Mowaffak Alraiyes Yasar Sattar Rodrigo Bagur Timir Paul Andrija Matetic Mamas A Mamas Nasser Lakkis M Chadi Alraies Source Type: research

Meta-Analysis Comparing Direct Oral Anticoagulants to Vitamin K Antagonists for The Management of Left Ventricular Thrombus
Expert Rev Cardiovasc Ther. 2021 Apr 8. doi: 10.1080/14779072.2021.1915134. Online ahead of print.ABSTRACTINTRODUCTION: To compare vitamin K antagonist (VKAs) and direct oral anticoagulants (DOACs) treatment in patients with left ventricular (LV) thrombus. The primary outcome was stroke or systemic embolism (SSE). Secondary outcomes were thrombus resolution, bleeding, and death.AREAS COVERED: Five observational studies were included (total n=700; VKAs n = 480; DOACs n = 220). There was a trend toward less SSE with VKAs compared to DOACs (5.2% vs. 9%; OR = 0.54, 95% CI= 0.29-1.01, p = 0.05). No significant difference betwee...
Source: Expert Review of Cardiovascular Therapy - April 8, 2021 Category: Cardiology Authors: Hesham K Abdelaziz Michael Megaly Maciej Debski Amr Abdelrahman Shehab Abdelaziz Diaa Kamal Billal Patel Ranjit More Tawfiq Choudhury Source Type: research

Clinical characteristics and stratification of the cerebrovascular accident risk among patients with atrial fibrillation in Colombia, 2011-2016.
Conclusions: AF primarily affects Colombian adults >65 years old. A high burden of comorbidities and a risk of thromboembolism were found in most patients; however, lack of treatment was evident in a large percentage of cases. PMID: 33430660 [PubMed - as supplied by publisher]
Source: Expert Review of Cardiovascular Therapy - January 14, 2021 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus.
Authors: Calderone D, Capodanno D, Angiolillo DJ Abstract INTRODUCTION: - Ticagrelor is an antiplatelet agent acting through direct and reversible competitive inhibition of the platelet P2Y12 receptor. While the clinical merits of ticagrelor in patients who experienced an acute coronary syndrome are widely accepted, its role in stable coronary artery disease is less established. Recently, large-scale trials of ticagrelor have been published in this setting, including a trial in patients with diabetes mellitus (DM). AREAS COVERED: - This review aims to inform about recent findings on ticagrelor, by appraising th...
Source: Expert Review of Cardiovascular Therapy - July 15, 2020 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

Utilization of percutaneous left atrial appendage closure in patients with atrial fibrillation: an update on patient outcomes.
Authors: Kleinecke C, Gloekler S, Meier B Abstract INTRODUCTION: Atrial fibrillation (AF) is associated with an increased risk of stroke, morbidity and overall mortality. So far, oral anticoagulation (OAC) is the standard of care for stroke prevention, either with vitamin K antagonists or with non-vitamin K oral anticoagulants (NOACs). The left atrial appendage (LAA) can be eliminated by epicardial or endocardial exclusion. Left atrial appendage closure (LAAC) represents a mechanical thromboprophylaxis - which has also been termed mechanical vaccination - against stroke, bleeding and death. AREAS COVERED: Studi...
Source: Expert Review of Cardiovascular Therapy - July 15, 2020 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

Icosapent Ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
Authors: Bazarbashi N, Miller M Abstract INTRODUCTION: Icosapent Ethyl (IPE) is a highly purified (>96%) form of eicosapentanoic acid, a marine-derived omega-3 fatty acid known to reduce serum triglyceride levels. Experimental and human studies also support anti-atherosclerotic properties of IPE including antioxidant, anti-inflammatory, endothelial and plaque stabilizing effects. In the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT)l),the addition of 4 grams IPE daily resulted in a 25% reduction in cardiovascular events beyond statins and other standard of care therapies. ...
Source: Expert Review of Cardiovascular Therapy - April 2, 2020 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

Predictors of adverse outcomes after transcatheter mitral valve replacement.
Authors: Overtchouk P, Piazza N, Granada JF, Modine T Abstract Introduction: Transcatheter mitral valve replacement (TMVR) is still a recent technology with numerous unknowns but also great promises. The risk of complications reported in observational studies have limited its adoption by interventional cardiology and surgical communities. Areas covered: Some of the major setbacks of TMVR are complications related to the devices and those related to the pathway. Device-related complications include left ventricle outflow tract (LVOT) obstruction, transcatheter heart valve (THV) dislocation or embolization, thrombosi...
Source: Expert Review of Cardiovascular Therapy - August 15, 2019 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

Edoxaban for the prevention of stroke in patients with atrial fibrillation.
Authors: Cervantes CE, Merino JL, Barrios V Abstract INTRODUCTION: Edoxaban is the last direct oral anticoagulant marketed for the prevention of stroke among patients with nonvalvular atrial fibrillation (AF). Areas covered: ENGAGE AF-TIMI 48 was the pivotal clinical trial that led to the approval of edoxaban 60 mg once daily. After the publication of this study, a great number of substudies and post hoc analyses have been published, together with some observational studies. The aim of this review was to update the current evidence about the use of edoxaban in AF patients. Expert commentary: In the ENGAGE AF-TIMI 4...
Source: Expert Review of Cardiovascular Therapy - March 24, 2019 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

Is it safe to stop oral anticoagulation after catheter ablation for atrial fibrillation?
Authors: Romero J, Avendano R, Diaz JC, Taveras J, Lupercio F, Di Biase L Abstract INTRODUCTION: Atrial fibrillation is the most common arrhythmia worldwide. Its increasing prevalence has made the use of oral anticoagulants for stroke prevention routine, however the use of them after the blanking period of catheter ablation remains uncertain. Areas covered: This review outlines the pros and cons of stopping oral anticoagulation after catheter ablation. Major databases such as Pubmed or Embase were used. The most relevant articles published were used along with major recommendations of society guidelines. Authors wi...
Source: Expert Review of Cardiovascular Therapy - November 23, 2018 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

Neurological complications associated with left ventricular assist device therapy.
Authors: Goodwin K, Kluis A, Alexy T, John R, Voeller R Abstract INTRODUCTION: Associated with significant morbidity and mortality, neurological complications in adult patients with left ventricular assist devices (LVAD) approaches a prevalence as high as 25%. As the number of individuals using LVAD support grows, it is increasingly important for providers to understand the hematologic and hemodynamic changes associated with LVAD implantation, the risk factors for neurological complications and their mitigation strategies. Areas covered: PubMed searches were completed using the terms 'Left ventricular assist device...
Source: Expert Review of Cardiovascular Therapy - November 15, 2018 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research